Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just a thought

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Apr 21, 2021 3:21pm

180 Views

Post# 33038643

RE:RE:RE:Just a thought

MrMugs
Your point on ownership is spot on in regards to reporting regulations which hopefully will cull this thought that a BP would try to tank the stock / manipulate it (government would be all over them)..., your point #3 -- "There's a leak that BP is looking to buy ATE and the stock starts to climb.". is very likely as more suitors come to the table. Chances of loose lips happen. I'd point to Mulesoft aquisition and stock price just before it was officially announced by CRM (and who says they planned to PR it that day...) eventually word gets out...

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec